NATIONAL PLAN TO ADDRESS ALZHEIMER'S DISEASE: 2017 UPDATE. Strategy 1.D: Coordinate Research with International Public and Private Entities

09/01/2017

Innovative Planning Tool Expanded. The International Alzheimer's Disease Research Portfolio (IADRP) -- a free, searchable database providing a global overview of AD research and funding -- is an invaluable tool for assessing and planning AD research projects. Funding organizations, researchers, and advocates are discovering IADRP's merits to help them coordinate strategies, leverage resources, avoid duplication, and identify promising areas of growth. Since NIH launched the database in 2012, in collaboration with the Alzheimer's Association, IADRP has amassed data on nearly 7,000 unique projects from 2008 through 2016, reflecting more than $5.7 billion in research funding worldwide. The number of contributors is growing, too. During the past 5 years, more than 35 funding organizations across 11 countries have joined the IADRP effort.The Common Alzheimer's Disease Research Ontology used in IADRP is also undergoing a significant update to the topic and themes that are used to categorize AD and ADRD funding data. The changes will reflect current research investment, as well as highlight emerging areas of science.

For more information, see:

________________________________________

Dementia with Lewy Bodies Consortium Annual Meeting. The first annual meeting of the newly createdDementia with Lewy Bodies (DLB) Consortium was held in early 2017. The funding for the consortium comes from NIH, NIA and the National Institute of Neurological Disorders and Stroke (NINDS), and the annual meeting is funded by the LBDA. This Consortium fills a vital gap in LBD research infrastructure.

For more information, see:

________________________________________

Late-Stage Alzheimer's Drug Pipeline. In March 2016, the UsAgainstAlzheimer's network ResearchersAgainstAlzheimer's (RA2) released an analysis of AD drugs in Phase 3 clinical trials and, in September 2016, an analysis of Phase 2 drugs. These reports described to patients, caregivers and researchers the drugs that could potentially reach the market in the next 5 years and explored whether our health care system would be ready for them. RA2 presented an updated report on Phase 2 and Phase 3 drugs in development at the Alzheimer's Association International Conference (AAIC) in London in July 2017.

________________________________________

Global Alzheimer's Platform Updates. In October 2016, the Global Alzheimer's Platform (GAP) Foundation fully implemented its novel recruitment model to increase referrals to the University of Kansas Alzheimer's Disease Center (KU ADC) through the establishment of the Memory Strings Kansas City Alliance. The model strives to develop and support a community-wide culture to support AD trials and continually drive appropriate referrals to research centers in the GAP network. Key local Alliance members include committed principal investigators; health care professionals and health insurers; community-based organizations that support African Americans and Latinos; federal, state and local government officials; leaders of commercial entities, non-government organizations, and respected individuals; and those interested in funding local research efforts. The Alliance focus on primarily activating primary care physicians has produced encouraging results: Q4 2016 referrals were up 200% at KU ADC and enrollments were up 150% when compared to Q4 2015 results. GAP has committed to roll-out this model in four more communities is 2017. GAP is building a global network of optimized clinical trial sites -- now numbering nearly 50 -- that are certified to meet industry-accepted quality and performance criteria.

________________________________________